新生儿硬肿症脂质过氧化物变化的观察

为探讨脂质过氧化损伤及自由基在新生儿硬肿症发病机理中的作用，将观察对象分为疾病组和对照组，疾病组于入院时，对照组于出生后１周内取静脉血检测血浆脂质过氧化物及红细胞超氧化物歧化酶含量。     

静脉毒瘾者84例HGV感染状况

目的调查庚型肝炎病毒（ＨＧＶ）在静脉毒瘾者中的感染状况。方法采用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）检测８４例静脉毒瘾者血浆标本。ＨＧＶＲＮＡ经热变性法提取后逆转录为ｃＤＮＡ，在ＨＧＶ５′非编码区（５′ＮＣＲ）设计两对引物进行巢式扩增，产物为２３８ｂｐ，并经限制性内切酶ＨｐａⅡ鉴定扩增产物来自ＨＧＶ。结果８４例中有１５例为ＨＧＶＲＮＡ阳性，阳性率为１７．９％。ＨＧＶＲＮＡ阳性病例中１１例合并丙型肝炎病毒感染（１１／１５）。结论静脉毒瘾者是ＨＧＶ感染的高危人群；不洁注射是获得ＨＧＶ感染的重要途径。     

实验家兔莱姆病血液学研究

本实验复制了莱姆病实验家兔模型，对血液生化23项进行了动态观察。结果表明，血液中谷丙转氨酶、γ-谷氨酰转肽酶、乳酸脱氢酶、谷草转氨酶、β-羟丁酸脱氢酶、磷酸肌酸激酶、胆固醇、尿素氮随病情加重而升高。葡萄糖、尿酸、磷随病情加重而减低。     

石家庄地区汉族人群DIS80(pMCT118)位点VNTR基因频率分布调查

本文采用ＰＣＲ技术对石家庄地区２１６名无关个体ＤＩＳ８０（ｐＭＣＴ１１８）位点扩增片段长度多态性的等位基因频率进行调查。ＰＣＲ扩增产物采用聚丙烯酰胺凝胶电泳分型及溴化乙锭染色，共检出７０种基因型，２５个等位基因，其中以１８、２４、３０三个等位基因频率最高。将本文结果与日本人群在ＤＩＳ８０（ｐＭＣＴ１１８）位点多态性结果进行比较，石家庄地区汉族人群ＤＩＳ８０（ｐＭＣＴ１１８）位点基因频率分布符合ＨａｒｄｙＷｅｉｎｂｅｒｇ平衡定律，该位点非父排除率为０．７１，个体识别率为０．９，杂合度为０．８５。     

尿激酶溶栓对急性心肌梗死患者单核细胞组织因子表达的影响

目的 :了解冠心病患者外周循环单核细胞组织因子 (TF)表达与冠心病病情的关系 ;观察溶栓治疗对急性心肌梗死患者单核细胞TF表达的影响。方法 :测定了 2 2例稳定型心绞痛 (SA)患者 ,2 1例不稳定型心绞痛(UA)患者 ,1 5例急性心肌梗死 (AMI)患者用尿激酶溶栓前及溶栓后 ,1 8例健康人外周循环单核细胞组织因子阳性率。单核细胞组织因子阳性率测定用免疫荧光染色及流式细胞术。结果 :SAP组 ,UAP组和AMI组单核细胞TF阳性率高于对照组 ,UAP组和AMI组单核细胞TF阳性率高于SAP组 ,单核细胞TF阳性率与冠心病病情显著相关。急性心肌梗死患者溶栓后 2h单核细胞TF阳性率升高。结论 :外周血单核细胞TF的表达与冠心病病情严重程度密切相关 ;急性心肌梗死患者溶栓治疗后单核细胞TF的表达进一步增强 ,这可能是溶栓后凝血酶活化的原因之一。     

乳酸林格氏液、高渗盐水和全血对失血性休克犬血液动力学的影响

以失血性休克犬为研究对象，比较乳酸林格氏液（LR）、高渗盐水（HS）和全血（WB）对其血液动力学的影响。经右颈外静脉插入Swan-Ganz飘浮导管，分别在全身氧供（DO2）恢复至休克前水平时，以及液体复苏后5、10、15、30、60和120min时测量动物的各项血液动力学指标。结果显示，HS仅需要11．83ml/kg的液体量，在4．97min时即可使休克犬的DO2恢复至休克前的水平，而LR组和WB组则分别需要52．08ml/kg和23．33ml/kg的液体量，在20．83min和9．33min时才能使休克犬的DO2恢复至休克前的水平。3组动物在DO2恢复至休克前水平时其血液动力学指标均能恢复至休克前的水平。提示高渗盐水比乳酸林格氏液和全血更适合失血性休克患者的早期紧急液体复苏治疗。     

胃癌组织端粒酶活性与催化亚基hTERT表达的关系

研究胃癌、胃黏膜肠化生及正常黏膜组织端粒酶活性与人端粒酶催化亚基(hTERT)表达的相关性及端粒酶激活在胃癌发生中的作用.方法:通过端粒重复序列扩增(TRAP)和逆转录聚合酶链反应(RT -PCR)方法测定3种胃癌细胞株、26例胃癌、10例胃黏膜肠化生和36例正常胃黏膜组织标本端粒酶活性和hTERT表达.结果:3种胃癌细胞株、24例胃癌组织有端粒酶活性;4例肠化生端粒酶活性较弱;36例正常胃黏膜标本未测到端粒酶活性.hTERT在26例胃癌组织、5例肠化胃黏膜中表达;正常胃黏膜无表达.端粒酶活性、hTERT表达与肿瘤的分期和病理分级无关.结论:hTERT在肿瘤形成的早期阶段表达,端粒酶的激活是胃癌形成的关键步骤.     

Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit.

BACKGROUND: The current manual sample processing method recommended for use with the TRUGENE HBV Genotyping Kit (TRUGENE HBV; Bayer HealthCare LLC, Tarrytown, NY) is labor-intensive and may be prone to specimen cross-contamination. Recent evaluations of the MagNA Pure LC (MP; Roche Applied Science, Indianapolis, IN) suggest that it is suitable for automated, contamination-free extraction and purification of viral nucleic acids from large-volume (1.0 mL) serum or plasma specimens. OBJECTIVES: We evaluated the MP Total Nucleic Acid Isolation Kit--Large Volume (Roche Applied Science) in conjunction with TRUGENE HBV to establish the analytical sensitivity (threshold titer) of the assay, in HBV DNA International Units (IU)/mL, for obtaining consistent, interpretable sequence data from TRUGENE HBV. STUDY DESIGN: HBV analytical standards, prepared as 10 replicates (1.0 mL each) at each of the following concentrations: 200, 1000, 5000, and 10,000 IU/mL, were processed by MP and analyzed by TRUGENE HBV according to manufacturer's instructions. Performance of TRUGENE HBV used in conjunction with MP sample processing was evaluated further using 22 clinical serum specimens containing low titers of HBV DNA. RESULTS: All replicates of HBV analytical standards at 1000, 5000, and 10,000 IU/mL yielded interpretable TRUGENE HBV sequences, whereas interpretable sequences were obtained in 90% (9 of 10) of the replicates at 200 IU/mL. TRUGENE HBV sequences were interpretable in 86% (19 of 22) of the clinical specimens studied. CONCLUSIONS: MP sample processing is efficient and suitable for use with TRUGENE HBV. When combined with MP sample processing, TRUGENE HBV yielded interpretable sequences from HBV analytical standards and clinical serum specimens with HBV DNA titers of > or =200 IU/mL.     

Pancreatic cancer–Palliative therapy: surgery (bypass/resection)

Objective: We compare the outcome of palliative pancreaticoduodenectomy and palliative surgical bypass in patients with advanced pancreatic carcinoma in our hospital. Recent published related articles are also reviewed. Methods: A respective analysis was performed comparing the perioperative parameters and outcome of 20 patients who underwent pancreaticoduodenectomy with a gross suspected cancer residue and 30 patients who underwent a surgical bypass, all of the patients were diagnosed as in advanced stages intra-operatively. Results: The two groups were comparable with patient characteristics, including age, gender, initial symptoms and concomitant major organ diseases. Tumors are similar in size and intra-operatively diagnosed as in advanced stages in both groups. All of the patients in the resection group were microscopically proved having cancer residue. One postoperative mortality occurred in the resection group (5%), zero in the bypass group (P > 0.05). Overall complications were significantly higher in the resection group (30% vs. 0, P < 0.01), including 2 patients developed Acute Respiratory Distress Syndrome (ARDS), zero in the bypass group (P < 0.01); hemorrhage and transfusions in the resection group were much more than that in the bypass group (P < 0.05). Hospital stay after resection was significantly longer than bypass (20 vs. 12 days, P < 0.01). Hospital fee after resection was 4 times more than after bypass (median 61.500 vs. 15. 300 yuan, P < 0.01). Survival was significantly longer after resection (median 12.2 vs. 7.1 months, P < 0.01). Conclusion: Our results show that palliative resection in advanced pancreatic carcinoma lengthens the survival time of the patients, but this is paid for significantly higher complications than bypass.